CytomX Therapeutics, Inc.
CTMX
$4.00
$0.194.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -68.04% | -63.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -68.04% | -63.36% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -68.04% | -63.36% | |||
| SG&A Expenses | -2.94% | -29.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.96% | -29.52% | |||
| Operating Income | -1,126.13% | -105.68% | |||
| Income Before Tax | -15,472.53% | -100.39% | |||
| Income Tax Expenses | -7.94% | 1.61% | |||
| Earnings from Continuing Operations | -9,139.61% | -100.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9,139.61% | -100.65% | |||
| EBIT | -1,126.13% | -105.68% | |||
| EBITDA | -1,564.96% | -104.08% | |||
| EPS Basic | -7,083.33% | -100.44% | |||
| Normalized Basic EPS | -13,325.00% | -100.24% | |||
| EPS Diluted | -7,400.00% | -100.44% | |||
| Normalized Diluted EPS | -13,325.00% | -100.24% | |||
| Average Basic Shares Outstanding | 27.84% | 48.16% | |||
| Average Diluted Shares Outstanding | 27.84% | 48.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||